Peptide compounds having improved binding affinity to somatostatin receptors
US7122622B2 · kind B2 · utility
2Cited by
8References
20Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 16, 2003 |
| Grant date | Oct 17, 2006 |
| Priority date | — |
| Expiry date | Dec 26, 2023 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K14/6555
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention relates to a peptide compound having an improved binding affinity to somatostatin receptors, comprising a somatostatin analogue as the peptide and a chelating group covalently linked to the N-terminal free amino group of said peptide, wherein said somatostatin analogue carries an 1-naphthylalanine or a 3-benzothienylalanine residue in its 3-position. The invention further relates to said peptide compound labeled with a detectable element or with a therapeutic radionuclide, as well as to a diagnostic method and to a method for the therapeutic treatment of tumors, by using the labeled compounds.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.